- today
Ricardo Villares, Dimitri Kakabadse, Yasmina Juarranz, Rosa P. Gomariz, Carlos Martínez-A, and Mario Mellado
PNAS November 26, 2013 110 (48) E4619-E4627; https://doi.org/10.1073/pnas.1314985110
- Edited by Tak W. Mak, The Campbell Family Institute for Breast Cancer Research, Ontario Cancer Institute at Princess Margaret Hospital, University Health Network, Toronto, ON, Canada, approved October 18 2013 (received for review August 9, 2013)
Abstract
Evidence supports a relationship between the neuroendocrine and the immune systems. Data from mice that overexpress or are deficient in growth hormone (GH) indicate that GH stimulates T and B-cell proliferation and Ig synthesis, and enhances maturation of myeloid progenitor cells.
The effect of GH on autoimmune pathologies has nonetheless been little studied. Using a murine model of type 1 diabetes, a T-cell–mediated autoimmune disease characterized by immune cell infiltration of pancreatic islets and destruction of insulin-producing β-cells, we observed that sustained GH expression reduced prodromal disease symptoms and eliminated progression to overt diabetes.
The effect involves several GH-mediated mechanisms; GH altered the cytokine environment, triggered anti-inflammatory macrophage (M2) polarization, maintained activity of the suppressor T-cell population, and limited Th17 cell plasticity. In addition, GH reduced apoptosis and/or increased the proliferative rate of β-cells.
These results support a role for GH in immune response regulation and identify a unique target for therapeutic intervention in type 1 diabetes.
Reference / Link
- Villares, R., Kakabadse, D., Juarranz, Y., Gomariz, R. P., Martínez-A, C., & Mellado, M. (2013). Growth hormone prevents the development of autoimmune diabetes. Proceedings of the National Academy of Sciences of the United States of America (PNAS), 110(48), E4619–E4627. DOI
Research Quality Begins with Peptide Quality
At Particle Peptides, we believe that reliable research begins with reliable materials. That is why our research peptides are manufactured on cGMP-compliant production lines by a global pharmaceutical CDMO, and every batch undergoes independent third-party testing for:
- Purity
- Identity confirmation
- Peptide content
- Endotoxin levels
- Heavy metals (Class I & II)
- Microbial contamination (TAMC & TYMC)
Transparency and independently verified laboratory data form the foundation of high-quality scientific research.
Disclaimer: All Particle Peptides products are intended exclusively for scientific research and laboratory use. They are not intended for human or veterinary use, nor for the diagnosis, treatment, cure, or prevention of any disease.
